According to a recent LinkedIn post from ABM Respiratory Care, the company plans to participate in the Oklahoma University Health Respiratory Conference in Oklahoma City on Friday, February 27. The post highlights in-booth demonstrations of its BiWaze platform, including BiWaze Cough and BiWaze Clear airway clearance systems aimed at supporting patients from hospital to home.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn content emphasizes technical features such as a dual blower system that enables bi-directional control of inhalation and exhalation, and a closed breathing circuit designed to support mucus mobilization and aerosol deposition. This focus on clinical functionality and new study insights suggests ABM is positioning BiWaze as a differentiated solution in respiratory care, which could support pricing power and adoption in both acute and home-care settings.
From an investor perspective, conference visibility at an OU Health–hosted event may help expand clinical engagement with respiratory therapists and clinicians, potentially driving lead generation and trial use in hospital systems. If these interactions translate into institutional contracts or broader home-use adoption, ABM could see incremental revenue growth and stronger positioning in the airway clearance and lung health segments.
The post’s invitation to schedule demos for those not attending indicates an ongoing push to build a sales funnel beyond a single conference appearance. Sustained awareness and clinician education could enhance the company’s competitive standing versus other respiratory device manufacturers, though the LinkedIn update does not provide data on current sales traction or regulatory or reimbursement milestones, which remain key variables for investors to monitor.